Recursion licenses TxFM RNA foundation model to Tempus AI for oncology use in USD 12 million deal
Bitget2026/09/21 16:18- Recursion Pharmaceuticals expanded its data partnership with Tempus AI, extending the term to six years from the effective date.
- Revised annual license fees set at USD 14 million on each of the third, fourth, and fifth anniversaries, with at least USD 4 million paid in cash.
- Removed Recursion’s right to terminate for convenience; reduced the total unique de-identified records it can access over the term.
- Separate two-year oncology license grants Tempus use of Recursion’s TxFM RNA model; Tempus to pay USD 12 million in two installments.
- Tempus to provide access to de-identified pathology records with linked clinical data during the TxFM license term.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rising energy prices increase inflation risks, Reserve Bank of Australia expected to implement the fourth rate hike of the year next week
As rising energy prices further highlight upward inflation risks, economists state that the Reserve Bank of Australia will raise its key interest rate next week and warn that there could be another hike in November.
Ark Invest increased its holdings of Meta Platforms shares by approximately 38.15 million dollars yesterday.
British Pound consolidates vs USD; bearish bias remains amid divergent Fed-BoE outlook
AI pharmaceutical company Iambic (IAM.US), supported by Nvidia, applies for US IPO to advance three early-stage cancer drugs
Iambic Therapeutics Inc. has filed for an initial public offering (IPO) in the United States.
Crypto prices
More
